Klapper J A, Stanton J
Colorado Neurology and Headache Center, Denver 80218.
Headache. 1992 Jan;32(1):21-3. doi: 10.1111/j.1526-4610.1992.hed3201021.x.
This study examines the practicality and efficacy of dihydroergotamine mesylate (DHE) when self-administered subcutaneously in a population of refractory headache patients. Forty-three patients with chronic daily headache or migraine headache without aura, who had been taught self-injection of DHE either through the Raskin Protocol or in an outpatient headache clinic, were contacted by telephone and administered a questionnaire regarding usage and results from DHE injection. Ninety-two percent of patients could successfully administer DHE. Forty-six percent of patients experienced 90% or greater relief of pain and the majority of patients (77%) had greater than 50% relief. Emergency room use was decreased in 83% and 80% preferred DHE to their previous therapy. While side effects were common (79%), only four patients (9%) stopped DHE for this reason. No convincing evidence for the development of rebound headaches due to DHE was found in this sample.
本研究探讨了难治性头痛患者皮下自我注射甲磺酸二氢麦角胺（DHE）的实用性和疗效。通过电话联系了43例慢性每日头痛或无先兆偏头痛患者，他们曾通过拉斯金方案或在门诊头痛诊所接受过DHE自我注射培训，并向他们发放了一份关于DHE使用情况和注射结果的问卷。92%的患者能够成功注射DHE。46%的患者疼痛缓解90%或以上，大多数患者（77%）疼痛缓解超过50%。83%的患者减少了急诊室就诊次数，80%的患者更喜欢DHE而非之前的治疗方法。虽然副作用很常见（79%），但只有4例患者（9%）因此停止使用DHE。在该样本中未发现有令人信服的证据表明DHE会导致反弹性头痛。
